| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD30 |
| Clinical data | |
| Trade names | Adcetris |
| Other names | SGN-35, previously cAC10-vcMMAE |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611052 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6476H9930N1690O2030S40 (C68H105N11O15)3–5 |
| Molar mass | 149.2–151.8 kg/mol |
  (what is this?) (verify) | |
Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.[4] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.[5]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ Cite error: The named reference
Adcetris FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Adcetris EPARwas invoked but never defined (see the help page). - ^ "Seattle Genetics Submits BLA to FDA for brentuximab vedotin in relapsed or refractory hodgkin lymphoma and systemic ALCL". Fierce Biotech. 28 February 2011.
- ^ "Takeda and Millennium Announce Approval of Adcetris (Brentuximab Vedotin) in Switzerland". www.takedaoncology.com. Archived from the original on 4 June 2020. Retrieved 4 June 2020.